Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

被引：6

作者：

Hotta, Katsuyuki ^{[1
,2
]}

Ninomiya, Kiichiro ^{[1
]}

Ichihara, Eiki ^{[1
]}

Kiura, Katsuyuki ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[2] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 01期

基金：

日本学术振兴会;

关键词：

Lung cancer; Treatment; Re-biopsy; CISPLATIN-BASED CHEMOTHERAPY; LOW-VOLUME HYDRATION; SPATIOTEMPORAL T790M HETEROGENEITY; EGFR-MUTANT; PROSPECTIVE FEASIBILITY; OPEN-LABEL; EXPRESSION; MUTATIONS; ALECTINIB; 1ST-LINE;

D O I：

10.1007/s10147-018-1344-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. Thisreview reports that the significance of a re-biopsy varies depending on the clinical situation.

引用

页码：41 / 45

页数：5

共 50 条

[21] Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer
Sadik, Helen
Pritchard, Daryl
Keeling, Derry-Mae
Policht, Frank
Riccelli, Peter
Stone, Gretta
Finkel, Kira
Schreier, Jeff
Munksted, Susanne
JCO PRECISION ONCOLOGY, 2022, 6
[22] Serological investigation of the clinical significance of fascin in non-small-cell lung cancer
Teng, Yu
Xu, Shaofa
Yue, Wentao
Ma, Li
Zhang, Lina
Zhao, Xiaoting
Guo, Yinan
Zhang, Chunyan
Gu, Meng
Wang, Yue
LUNG CANCER, 2013, 82 (02) : 346 - 352
[23] Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
Nosaki, Kaname
Satouchi, Miyako
Kurata, Takayasu
Yoshida, Tatsuya
Okamoto, Isamu
Katakami, Nobuyuki
Imamura, Fumio
Tanaka, Kaoru
Yamane, Yuki
Yamamoto, Nobuyuki
Kato, Terufumi
Kiura, Katsuyuki
Saka, Hideo
Yoshioka, Hiroshige
Watanabe, Kana
Mizuno, Keiko
Seto, Takashi
LUNG CANCER, 2016, 101 : 1 - 8
[24] Current situation of re-biopsy in non small-cell lung cancer treated with EGFR-TKI.
Oguri, Tomoyo
Ohyanagi, Fumiyoshi
Takano, Natsuki
Kawashima, Yosuke
Kitazono, Satoru
Tambo, Yuichi
Yanagitani, Noriko
Horiike, Atsushi
Horai, Takeshi
Nishio, Makoto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] Advanced Non-Small-Cell Lung Cancer in the Elderly
Vamvakas, Lambros
Saloustros, Emmanouel
Karampeazis, Athanasios
Georgoulias, Vassilis
CLINICAL LUNG CANCER, 2009, 10 (03) : 158 - 167
[26] Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer
Yoo, Jinyoung
Shim, Byoung Yong
Yoo, Chang Young
Kang, Seok Jin
Lee, Kyo Young
KOREAN JOURNAL OF PATHOLOGY, 2009, 43 (05) : 435 - 440
[27] Atezolizumab in advanced non-small-cell lung cancer
Brower, Vicki
LANCET ONCOLOGY, 2017, 18 (08): : E434 - E434
[28] Pemetrexed in advanced non-small-cell lung cancer
Fuld, Alexander D.
Dragnev, Konstantin H.
Rigas, James R.
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1387 - 1402
[29] Afatinib in advanced non-small-cell lung cancer
Di Maio, Massimo
Gridelli, Cesare
Grossi, Francesco
Novello, Silvia
de Marinis, Filippo
LUNG CANCER MANAGEMENT, 2013, 2 (06) : 493 - 504
[30] Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
Somerfield, MR
Ihde, DC
Pfister, DG
Baker, S
Bernath, A
Brescia, FJ
Fontenot, E
Green, MR
Johnson, DH
Olak, J
Sause, W
Smith, TJ
Stover, D
Turrisi, AT
Waters, P
Winn, RJ
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) : 2996 - 3018

← 1 2 3 4 5 →